drugset / Trial / NCT00186589
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
Phase 1
Completed
30 enrolled
Stanford University
Biogen · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.
Timeline
- Start
- 2004-05
- Primary completion
- 2007-07
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | — | — |